FrancophonIA/ELRC3.0 huggingface dataset:
English: The small delay of gastric emptying with liraglutide may influence absorption of concomitantly administered oral medicinal products.
Croatian: Manja odgoda u pražnjenju želuca uz liraglutid mogla bi utjecati na apsorpciju istodobno primijenjenih peroralnih lijekova.
English: Untreated hyperglycaemic events eventually lead to hyperosmolar coma/diabetic ketoacidosis, which is potentially lethal.
Croatian: Neliječena hiperglikemija u konačnici vodi do hiperosmolarne kome/dijabetičke ketoacidoze, što može biti smrtonosno.
English: The following substances may reduce the Xultophy requirement:
Croatian: Sljedeće tvari mogu smanjiti potrebu za lijekom Xultophy:
English: Animal reproduction studies with insulin degludec have not revealed any differences between insulin degludec and human insulin regarding embryotoxicity and teratogenicity.
Croatian: Ispitivanja reprodukcije na životinjama s degludek inzulinom nisu pokazala nikakvu razliku između degludek inzulina i humanog inzulina s obzirom na embriotoksičnost i teratogenost.
English: Signs and symptoms of dehydration, including renal impairment and acute renal failure have been reported in clinical trials with GLP-1 receptor agonists including liraglutide, a component of Xultophy.
Croatian: Znakovi i simptomi dehidracije, uključujući oštećenje bubrega i akutno zatajenje bubrega, prijavljeni su u kliničkim ispitivanjima s agonistima GLP-1 receptora, uključujući liraglutid, sastavnicu lijeka Xultophy.
English: Xultophy cannot be recommended for use in patients with end-stage renal disease (see sections 5.1 and 5.2).
Croatian: Primjena lijeka Xultophy se ne može preporučiti u bolesnika sa zadnjim stadijem bubrežne bolesti (vidjeti dijelove 5.1 i 5.2).
English: Rates of confirmed hypoglycaemia were lower with Xultophy than with insulin degludec irrespective of the glycaemic control, see Figure 1.
Croatian: Stope potvrđene hipoglikemije bile su niže s lijekom Xultophy nego s degludek inzulinom, bez obzira na regulaciju glikemije, vidjeti Sliku 1.
English: • Test your blood or urine for ketones.
Croatian: • Provjerite ketone u krvi ili mokraći.
English: Inadequate dosing and/or discontinuation of antidiabetic treatment may lead to hyperglycaemia and potentially to hyperosmolar coma.
Croatian: Neodgovarajuće doziranje i/ili prekid terapije lijekovima za šećernu bolest može dovesti do hiperglikemije, a potencijalno i do hiperosmolarne kome.
English: Xultophy is therefore not recommended in these patients.
Croatian: Stoga se primjena lijeka Xultophy u takvih bolesnika ne preporučuje.
English: In the trial investigating Xultophy as add on to sulfonylurea the target was 4.0-6.0 mmol/L
Croatian: U ispitivanju u kojem se Xultophy primjenjivao kao dodatak sufonilureji, ciljna vrijednost iznosila je 4,0-6,0 mmol/l
English: Antibody formation has not been associated with reduced efficacy of Xultophy.
Croatian: Stvaranje protutijela nije povezano sa smanjenom djelotvornošću lijeka Xultophy.
English: Allergic reactions (manifested with signs and symptoms such as urticaria (0.3% of patients treated with Xultophy), rash (0.7%), pruritus (0.5%) and/or swelling of the face (0.2%)) have been reported for Xultophy.
Croatian: Kod primjene lijeka Xultophy prijavljene su alergijske reakcije (koje se manifestiraju znakovima i simptomima kao što su urtikarija (0,3% bolesnika liječenih lijekom Xultophy), osip (0,7%), pruritus (0,5%) i/ili oticanje lica (0,2%)).
English: Neonatal growth was reduced in rats while exposed to liraglutide, and persisted in the post-weaning period in the high dose group.
Croatian: Neonatalni rast bio je smanjen u štakora tijekom izloženosti liraglutidu i to se zadržalo tijekom razdoblja nakon odvikavanja od sisanja u skupini na visokoj dozi lijeka.
English: If you stop using Xultophy
Croatian: Ako prestanete primjenjivati Xultophy
English: Table 4 Results at 26-weeks - Transfer from GLP-1 receptor agonists
Croatian: Tablica 4 Rezultati u 26. tjednu - Prijelaz s liječenja agonistima GLP-1 receptora
English: Non-lethal thyroid C-cell tumours were seen in 2-year carcinogenicity studies in rats and mice.
Croatian: C-stanica štitnjače zabilježeni su u 2-godišnjim ispitivanjima kancerogenosti u štakora i miševa.
English: What Xultophy is and what it is used for What Xultophy is used for
Croatian: Što je Xultophy i za što se koristi
English: Liraglutide exposure was reduced in patients with renal impairment compared to individuals with normal renal function.
Croatian: Izloženost liraglutidu bila je smanjena u bolesnika s oštećenjem bubrega u usporedbi s osobama s normalnom bubrežnom funkcijom.
English: The trial was designed as a non-inferiority trial to exclude a pre-specified risk margin of 1.3 for the hazard ratio (HR) of MACE comparing insulin degludec to insulin glargine.
Croatian: Ispitivanje je bilo dizajnirano kao ispitivanje neinferiornosti kako bi se isključila unaprijed određena margina rizika od 1,3 za omjer hazarda za MACE uz degludek inzulin u odnosu na glargin inzulin.
English: Animal studies have shown that the transfer of liraglutide and metabolites of close structural relationship into milk was low.
Croatian: Ispitivanja na životinjama pokazala su nizak stupanj prijelaza liraglutida i strukturno sličnih metabolita u mlijeko.
English: • The pen scale shows you approximately how much solution is left in your pen.
Croatian: • Skala na brizgalici pokazuje Vam približno koliko je otopine preostalo u brizgalici.
English: Injection site reactions (including injection site haematoma, pain, haemmorrhage, erythema, nodules, swelling, discolouration, pruritus, warmth and injection site mass) have been reported in 2.6% of patients treated with Xultophy.
Croatian: Reakcije na mjestu injiciranja (uključujući hematom na mjestu injiciranja, bol, krvarenje, eritem, čvoriće, oticanje, promjenu boje, svrbež, toplinu i oteklinu na mjestu injiciranja) prijavljene su u 2,6% bolesnika liječenih lijekom Xultophy.
English: IDegLira Unchanged GLP-1 RA
Croatian: Nepromijenjena doza GLP-1 RA
English: Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin medicinal products, especially in patients with risk factors for development of cardiac failure.
Croatian: Zabilježeni su slučajevi zatajivanja srca kod primjene pioglitazona u kombinaciji s inzulinskim pripravcima, osobito u bolesnika koji su imali rizične faktore za razvoj zatajivanja srca.
English: Xultophy as add-on to sulfonylurea alone or in combination with metformin were studied in a 26-week randomised, placebo-controlled, double-blind trial.
Croatian: Xultophy se kao dodatak sulfonilureji, samoj ili u kombinaciji s metforminom, ispitivao u 26-tjednom randomiziranom, placebom kontroliranom, dvostruko slijepom ispitivanju.
English: The results were similar for Xultophy and liraglutide.
Croatian: Rezultati su bili slični s lijekom Xultophy i liraglutidom.
English: Your pen delivers doses in increments of 1 dose step.
Croatian: Vaša brizgalica isporučuje doze u stupnjevima od 1 odmjernog koraka.
English: Changing the place where you inject each time may reduce the risk of these skin changes.
Croatian: Promjena mjesta injiciranja kod svake injekcije može smanjiti rizik od nastanka takvih promjena na koži.
English: • use too much Xultophy.
Croatian: • primijenite previše lijeka Xultophy.
English: Transfer from basal insulin (NPH, insulin detemir, insulin glargine)
Croatian: Prijelaz s bazalnog inzulina (NPH, detemir inzulin, glargin inzulin)
English: Table 2 Titration of Xultophy
Croatian: Tablica 2 Titracija lijeka Xultophy
English: There was no clinically relevant effect on the overall exposure of either ethinylestradiol or levonorgestrel.
Croatian: Nije bilo klinički značajnog učinka na ukupnu izloženost etinilestradiolu ili levonorgestrelu.
English: Xultophy is a medicine that contains insulin degludec and liraglutide.
Croatian: Xultophy je lijek koji sadrži degludek inzulin i liraglutid.
English: Only the dose counter and dose pointer will show how many dose steps you select per dose.
Croatian: Jedino će brojčanik doze i pokazivač doze pokazati koliko ste odmjernih koraka odabrali po dozi.
English: Non-clinical data reveal no special hazards for human based on conventional studies of safety pharmacology, repeat-dose toxicity, or genotoxicity.
Croatian: Neklinički podaci ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja sigurnosne farmakologije, toksičnosti ponovljenih doza ili genotoksičnosti.
English: Add-on to oral glucose-lowering medicinal products Adding Xultophy to metformin alone or in combination with pioglitazone in a 26-week randomised, controlled, open-label trial resulted in 60.4% of patients treated with Xultophy reaching a target of HbA1c <7% without confirmed hypoglycaemic episodes after 26 weeks of treatment.
Croatian: Dodatak peroralnim lijekovima za snižavanje razine glukoze Dodavanjem lijeka Xultophy metforminu samom ili u kombinaciji s pioglitazonom u 26-tjednom randomiziranom, kontroliranom, otvorenom ispitivanju postiglo se da je 60,4% bolesnika liječenih lijekom Xultophy postiglo ciljnu vrijednost HbA1c <7% bez potvrđenih epizoda hipoglikemije nakon 26 tjedana liječenja.
English: • Skin changes where you give the injection (‘lipodystrophy') - the fatty tissue under the skin may shrink (‘lipoatrophy') or get thicker (‘lipohypertrophy').
Croatian: • promjene na koži na mjestu injiciranja (‘lipodistrofija') - potkožno masno tkivo može se smanjiti (‘lipoatrofija') ili povećati (‘lipohipertrofija').
English: A single dose administration of digoxin 1 mg with liraglutide resulted in a reduction of digoxin AUC by 16%; Cmax decreased by 31%.
Croatian: Primjena jedne doze digoksina od 1 mg s liraglutidom rezultirala je smanjenjem AUC digoksina za 16%; Cmax se smanjio za 31%.
English: Xultophy is a combination product consisting of insulin degludec and liraglutide having complementary mechanisms of action to improve glycaemic control.
Croatian: Xultophy je kombinirani lijek koji se sastoji od degludek inzulina i liraglutida s komplementarnim mehanizmima djelovanja radi poboljšanja regulacije glikemije.
English: DEVOTE was a randomised, double-blind, and event-driven clinical trial with a median duration of 2 years comparing the cardiovascular safety of insulin degludec versus insulin glargine (100 units/mL) in 7,637 patients with type 2 diabetes mellitus at high risk of cardiovascular events.
Croatian: Ispitivanje DEVOTE bilo je randomizirano, dvostruko slijepo kliničko ispitivanje vođeno događajima, s medijanom trajanja od 2 godine, u kojem se uspoređivala kardiovaskularna sigurnost degludek inzulina u odnosu na glargin inzulin (100 jedinica/ml) u 7637 bolesnika sa šećernom bolešću tipa 2 i visokim rizikom od kardiovaskularnih događaja.
English: The following reflects the pharmacokinetic properties of Xultophy unless stated that the presented data is from administration of insulin degludec or liraglutide alone.
Croatian: Sljedeći podaci odražavaju farmakokinetička svojstva lijeka Xultophy, osim ako nije navedeno da se prikazani podaci odnose na primjenu samog degludek inzulina ili samog liraglutida.
English: Paediatric population There is no relevant use of Xultophy in the paediatric population.
Croatian: Pedijatrijska populacija Nije opravdana primjena lijeka Xultophy u pedijatrijskoj populaciji.
English: The curves are mean hypo rates from a negative binomial model with unique treatment trajectories and the symbols are observed hypo rates vs. mean HbA1c by quartiles.
Croatian: Krivulje predstavljaju srednje vrijednosti hipoglikemije iz negativnog binomnog modela s jedinstvenim putanjama liječenja, a simboli predstavljaju primijećene stope hipoglikemije u odnosu na srednje vrijednosti HbA1c po kvartilima.
English: HbA1c (%) at end of treatment
Croatian: HbA1c (%) na kraju liječenja
English: Pen label
Croatian: Papirnata naljepnica
English: 3 mL solution in a cartridge (type 1 glass) with a plunger (halobutyl) and a stopper (halobutyl/polyisoprene) contained in a pre-filled multidose disposable pen made of polypropylene, polycarbonate and acrylonitrile butadiene styrene.
Croatian: 3 ml otopine u ulošku (staklo tipa 1) s klipom (halobutil) i čepom (halobutil/poliizopren) nalazi se u jednokratnoj, višedoznoj napunjenoj brizgalici od polipropilena, polikarbonata i akrilonitril butadien stirena.
English: Xultophy is administered subcutaneously by injection in the thigh, the upper arm or the abdomen.
Croatian: Xultophy se primjenjuje supkutanom injekcijom u bedro, nadlakticu ili abdomen.
English: • Low blood sugar (very common: may affect more than 1 in 10 people).
Croatian: • niska razina šećera u krvi (vrlo često: može se javiti u više od 1 na 10 osoba) Ako dođe do pada razine šećera u krvi, mogli biste se onesvijestiti.
English: This may prevent blocked needles, contamination, infection and inaccurate dosing.
Croatian: Time možete spriječiti začepljenje igala, onečišćenje, infekciju i neispravno doziranje.
English: Postprandial glucose reduction was confirmed in a 4 hour standardised meal test substudy in patients uncontrolled on metformin alone or in combination with pioglitazone.
Croatian: Postprandijalno smanjenje razine glukoze potvrđeno je četverosatnim testom sa standardiziranim obrokom u podispitivanju s bolesnicima nedovoljno reguliranih metforminom, samim ili u kombinaciji s pioglitazonom.
English: Non-clinical studies with liraglutide have shown a treatment-related reduction of neonatal growth in suckling rat pups (see section 5.3).
Croatian: Neklinička ispitivanja s liraglutidom pokazala su s liječenjem povezano smanjenje neonatalnog rasta u dojene mladunčadi štakora (vidjeti dio 5.3).
English: For study results with respect to combinations, effects on glycaemic control, and the populations studied, see sections 4.4, 4.5 and 5.1.
Croatian: učinke na kontrolu glikemije te ispitivane populacije, vidjeti dijelove 4.4, 4.5 i 5.1. 4.2 Doziranje i način primjene
English: Non-clinical safety data revealed no safety concern for humans based on repeated dose toxicity studies.
Croatian: Neklinički podaci o sigurnosti primjene nisu ukazali na poseban rizik za sigurnost ljudi na temelju ispitivanja toksičnosti ponovljenih doza.
English: Liraglutide did not change the overall exposure of atorvastatin to a clinical relevant degree following single dose administration of atorvastatin 40 mg.
Croatian: Liraglutid nije promijenio ukupnu izloženost atorvastatinu u klinički značajnoj mjeri nakon primjene jedne doze atorvastatina od 40 mg.
English: Combination of pioglitazone and insulin medicinal products
Croatian: Kombinacija pioglitazona i inzulinskih pripravaka
English: dose steps selected
Croatian: odabrana 2 odmjerna koraka
English: Always remove the needle from your pen after each injection.
Croatian: Uvijek skinite iglu s brizgalice nakon svakog injiciranja.
English: Tell your doctor if you:
Croatian: Obavijestite svog liječnika:
English: Transfer from GLP-1 receptor agonist to Xultophy compared to unchanged GLP-1 receptor agonist therapy (dosed according to label) were studied in a 26-weeks randomised, open-label trial in patients with type 2 diabetes mellitus inadequately controlled on a GLP-1 receptor agonist and metformin alone (74.2%) or in combination with pioglitazone (2.5%), sulfonylurea (21.2%) or both (2.1%).
Croatian: Prijelaz s liječenja agonistom GLP-1 receptora na Xultophy u usporedbi s nepromijenjenom terapijom agonistom GLP-1 receptora (doziranim kako je odobreno) ispitivale su se u 26-tjednom randomiziranom, otvorenom ispitivanju u bolesnika sa šećernom bolešću tipa 2 nedovoljno reguliranih agonistom GLP-1 receptora i metforminom, samim (74,2%) ili u kombinaciji s pioglitazonom (2,5%), sulfonilurejom (21,2%) ili oba ta lijeka (2,1%).
English: • Unscrew the needle and dispose of it carefully as instructed by your doctor or nurse.
Croatian: • Odvijte iglu i pažljivo je bacite u otpad, sukladno uputama koje ste dobili od svog liječnika ili medicinske sestre.
English: The pharmacokinetic profile of Xultophy is consistent with once-daily dosing and steady-state concentration of insulin degludec and liraglutide is reached after 2-3 days of daily administration.
Croatian: Farmakokinetički profil lijeka Xultophy u skladu je s doziranjem jednom dnevno, a koncentracija degludek inzulina i liraglutida u stanju dinamičke ravnoteže dostiže se nakon 2-3 dana svakodnevne primjene.
English: The reduction in HbA1c from baseline to 52 weeks was 1.84% with Xultophy with an estimated treatment difference of -0.65% compared to liraglutide (p<0.0001) and -0.46% compared to insulin degludec (p<0.0001).
Croatian: Smanjenje HbA1c od početnih vrijednosti do 52. tjedna bilo je 1,84% s lijekom Xultophy, uz procijenjenu razliku između liječenja od -0,65% u usporedbi s liraglutidom (p<0,0001) i -0,46% u usporedbi s degludek inzulinom (p<0,0001).
English: • Xultophy is given as an injection under the skin (subcutaneously).
Croatian: • Xultophy se primjenjuje potkožnom (supkutanom) injekcijom.
English: Patients must be instructed to always check the pen label before each injection to avoid accidental mix-ups between Xultophy and other injectable diabetes medicinal products.
Croatian: Bolesnicima se mora objasniti da prije svakog injiciranja uvijek provjere naljepnicu na brizgalici kako ne bi došlo do slučajne zamjene lijeka Xultophy i drugih lijekova za šećernu bolest koji se injiciraju.
English: How Xultophy works
Croatian: Kako Xultophy djeluje
English: Figure 7 Forest plot of analysis of the composite 3-point MACE and individual cardiovascular endpoints in DEVOTE
Croatian: Slika 7 Grafikon raspona pouzdanosti (engl. forest plot) za analizu objedinjenih trokomponentnih MACE događaja i pojedinačnih kardiovaskularnih mjera ishoda u ispitivanju DEVOTE
English: This may indicate a blocked or damaged needle.
Croatian: To može značiti da je igla začepljena ili oštećena.
English: Primary analysis (3-point MACE) CV Death
Croatian: Primarna analiza (3-dijelni MACE)
English: It is not known if Xultophy passes into breast milk.
Croatian: Nije poznato izlučuje li se Xultophy u majčino mlijeko.
English: Overall, the pharmacokinetics of insulin degludec and liraglutide were not affected in a clinically relevant manner when administered as Xultophy compared with independent injections of insulin degludec and liraglutide.
Croatian: Sveukupno, na farmakokinetiku degludek inzulina i liraglutida nije klinički značajno utjecala njihova primjena u obliku lijeka Xultophy u usporedbi s primjenom zasebnih injekcija degludek inzulina i liraglutida.
English: Fast improvements in blood sugar control may make diabetic eye problems get worse for a short time.
Croatian: Naglo poboljšanje regulacije šećera u krvi može dovesti do kratkotrajnog pogoršanja problema s očima u osoba oboljelih od šećerne bolesti.
English: It is not known whether insulin degludec or liraglutide is excreted in human milk.
Croatian: Nije poznato izlučuje li se degludek inzulin ili liraglutid u majčino mlijeko.
English: If you stop using Xultophy this could lead to a very high blood sugar level, see the advice in section 4 ‘High blood sugar (hyperglycaemia)'.
Croatian: Ako prestanete primjenjivati Xultophy, to može dovesti do vrlo visoke razine šećera u krvi; pogledajte savjete u dijelu 4. ‘Visoka razina šećera u krvi (hiperglikemija)'.
English: A Endpoints with confirmed superiority of Xultophy vs comparator
Croatian: Mjere ishoda s potvrđenom superiornošću lijeka Xultophy u odnosu na usporedni lijek
English: • Injection site reactions.
Croatian: • reakcije na mjestu injiciranja.
English: • Inflamed gallbladder.
Croatian: • upala žučnog mjehura.
English: In three trials with patients inadequately controlled on basal insulin, systolic blood pressure was reduced by 5.4 mmHg with Xultophy and 1.7 mmHg with insulin degludec, with a statistically significant estimated treatment difference of -3.71 mmHg (p=0.0028), reduced by 3.7 mmHg with Xultophy vs 0.2 mmHg with insulin glargine, with a statistically significant estimated treatment difference of -3.57 mmHg (p<0.001) and reduced by 4.5 mmHg with Xultophy vs 1.16 mmHg with insulin glargine U100 plus insulin aspart, with a statistically significant estimated treatment difference of -3.70 mmHg (p=0.0003).
Croatian: U trima ispitivanjima provedenima u bolesnika nedovoljno reguliranih bazalnim inzulinom: sistolički krvni tlak snižen je za 5,4 mmHg uz Xultophy te za 1,7 mmHg uz degludek inzulin, što daje statistički značajnu procijenjenu razliku između liječenja od -3,71 mmHg (p=0,0028), sistolički krvni tlak snižen je za 3,7 mmHg uz Xultophy te za 0,2 mmHg uz glargin inzulin, što daje statistički značajnu procijenjenu razliku između liječenja od -3,57 mmHg (p<0,001), odnosno sistolički krvni tlak snižen je za 4,5 mmHg uz Xultophy te za 1,16 mmHg uz glargin inzulin od 100 jedinica u kombinaciji s aspart inzulinom, što daje statistički značajnu procijenjenu razliku između liječenja od -3,70 mmHg (p=0,0003).
English: The maximum allowed dose was 50 dose steps for Xultophy and 50 units for insulin degludec.
Croatian: Najveća dopuštena doza bila je 50 odmjernih koraka za Xultophy i 50 jedinica za degludek inzulin.
English: They may increase or decrease your blood sugar level.
Croatian: Ovi lijekovi mogu povećati ili smanjiti razinu šećera u krvi.
English: • The other ingredients are glycerol, phenol, zinc acetate, hydrochloric acid and sodium hydroxide (for pH adjustment), and water for injections.
Croatian: • Drugi sastojci su glicerol, fenol, cinkov acetat, kloridna kiselina i natrijev hidroksid (za podešavanje pH) i voda za injekcije.
English: The pharmacokinetics of liraglutide was evaluated in patients with varying degrees of hepatic impairment in a single-dose trial.
Croatian: Liraglutid Farmakokinetika liraglutida procjenjivala se u bolesnika s različitim stupnjevima oštećenja jetre u ispitivanju s jednom dozom lijeka.
English: Liraglutide stimulates insulin secretion and lowers inappropriately high glucagon secretion in a glucose-dependent manner.
Croatian: Liraglutid potiče lučenje inzulina i snižava neprimjereno visoko lučenje glukagona u ovisnosti od glukoze.
English: In patients inadequately controlled on sulfonylurea alone or in combination with metformin, the reduction was 3.5 mmHg with Xultophy and 3.2 mmHg with placebo.
Croatian: U bolesnika nedovoljno reguliranih sulfonilurejom samom ili u kombinaciji s metforminom smanjenje je iznosilo 3,5 mmHg uz Xultophy te 3,2 mmHg uz placebo.
English: The rate of nocturnal hypoglycaemic events was similar with Xultophy and insulin degludec treatment.
Croatian: Stopa noćnih hipoglikemijskih događaja bila je slična s lijekom Xultophy i degludek inzulinom.
English: Solution for injection Multipack: 10 (2 packs of 5) 3 mL pre-filled pens
Croatian: Višestruko pakiranje: 10 (2 pakiranja po 5) napunjenih brizgalica od 3 ml
English: Insulin (units) Liraglutide (mg) Estimated difference, basal insulin dose
Croatian: Inzulin (jedinice) Liraglutid (mg) Procijenjena razlika, doza bazalnog inzulina
English: If you forget a dose, inject the missed dose when discovering the mistake, ensuring a minimum of
Croatian: Ako ste zaboravili primijeniti Xultophy Ako ste zaboravili primijeniti jednu dozu, injicirajte izostavljenu dozu čim utvrdite pogrešku, pazeći da između dvije doze protekne najmanje 8 sati.
English: Rate of hypoglycaemia (events per PYE)
Croatian: Stopa hipoglikemije (događaji za PYE)
English: See advice in ‘Low blood sugar (hypoglycaemia)' further down in this section.
Croatian: Pogledajte savjete u odlomku ‘Niska razina šećera u krvi (hipoglikemija)' u nastavku ovog dijela.
English: Pack sizes of 1, 3, 5 and multipack containing 10 (2 packs of 5) pre-filled pens.
Croatian: Veličine pakiranja od 1, 3 ili 5 brizgalica i višestruko pakiranje koje sadrži 10 (2 pakiranja po 5) napunjenih brizgalica.
English: The maximum allowed dose in the trial was 50 dose steps for Xultophy whereas there was no maximum dose for insulin glargine.
Croatian: Najveća dopuštena doza u ispitivanju bila je 50 odmjernih koraka za Xultophy, dok za glargin inzulin nije bila određena najveća doza.
English: The mechanism of blood glucose-lowering also involves a minor delay in gastric emptying.
Croatian: Mehanizam snižavanja glukoze u krvi također uključuje i blago odgođeno pražnjenje želuca.